New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice